A Critical Re-Evaluation of "Pathway-Selective 5-HT1A Receptor Agonist as a Rapid Antidepressant Strategy" by Wang et al., Cell 2025; doi:10.1016/j.cell.2025.10.022

This repository contains a comprehensive critical commentary on the article “Pathway-selective 5-HT1A receptor agonist as a rapid antidepressant strategy” by Wang C, Zhang N, Shao Y, et al. (Cell, 2025; doi:10.1016/j.cell.2025.10.022). Authored by Yiheng Wang, Ruihuang Wang, Zhiyang Zhou, and Shu-Feng Zhou, this work provides the most exhaustive independent evaluation to date of the mechanistic, methodological, and interpretational claims presented in the original publication. Because the study proposes a paradigm-shifting model—namely, that a biased 5-HT1A receptor agonist can engage β-arrestin2 to activate ERK–mTOR signaling and thereby produce rapid antidepressant effects—rigorous post-publication analysis is essential.

The commentary delivers a figure-by-figure critique, covering all Main Figures, Extended Data Figures, and Supplementary Figures, and interrogates the empirical basis for each mechanistic step proposed. Across molecular pharmacology, structural modeling, β-arrestin signaling assays, phospho-proteomics, electrophysiology, in vivo calcium imaging, behavioral testing, and cross-species comparison, the analysis highlights pervasive inconsistencies and methodological weaknesses. These include inadequate controls, pseudoreplication, absence of statistical correction, incomplete documentation of replicates, insufficient blinding and randomization, baseline mismatches among groups, and selective reporting of favorable results. Such weaknesses undermine the reliability of the data and challenge the validity of the mechanistic conclusions.

A central component of the critique concerns biological plausibility, demonstrating that the proposed mechanism is inconsistent with canonical 5-HT1A receptor biology, which is dominated by Gi/o signaling and exhibits weak β-arrestin recruitment. The rapid behavioral effects claimed cannot be reconciled with the timescales of ERK–mTOR signaling or with the ligand’s rapid brain clearance. The lack of anatomical specificity, absence of causal manipulations, and mismatch between molecular, circuit, and behavioral timescales further weaken the mechanistic model. Behavioral results are shown to be more consistent with nonspecific anxiolysis or arousal modulation than with antidepressant efficacy.

Beyond evaluating the validity of the study, this commentary addresses the broader implications for neuroscience, GPCR biology, and antidepressant drug discovery. It warns against conceptual overreach in biased agonism, highlights the dangers of interpreting neuromodulatory effects as structural plasticity, and underscores the need for interdisciplinary peer review that prioritizes mechanistic realism, statistical rigor, physiological coherence, and methodological transparency. The analysis reinforces the importance of critical post-publication review in maintaining the integrity of the scientific literature.

This Zenodo record provides the full commentary, suitable for citation and scholarly use, and aims to promote scientific transparency, improve methodological standards, and foster informed dialogue within the neuropharmacology community.